Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994046 | 0.85 | SMN1; SMN2 (0.48) | POLBSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8425406 | 0.81 | POLB (0.47) | POLBTDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11379564 | 0.80 | KMT2A (0.40) | POLBBRD4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7332254 | 0.79 | TAAR1 (0.54) | POLBTDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4461404 | 0.76 | SMN1; SMN2 (0.51) | POLBTDP1BRD4SMN1; SMN2NPC1 | |
| SCHEMBL12530774 | 0.76 | POLB (0.47) | POLBTDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL187684 | 0.75 | ALOX5 (0.51) | POLBTDP1NPC1RAB9AALDH1A1 | |
| SCHEMBL11550988 | 0.75 | POLB (0.44) | POLBTDP1SMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8763040 | 0.74 | SMN1; SMN2 (0.50) | POLBTDP1BRD4SMN1; SMN2NPC1 | |
| SCHEMBL6748905 | 0.74 | CYP2A6 (0.44) | RAB9AGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6602900-B2 | F-type prostaglandins as ocular hypotensives | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2002-12-26 | — | — | US | disclosed |
| US-6310087-B2 | TREATING GASTRIC OR DUODENAL ULCER, OSTEOPOROSIS, CONSTIPATION, RENAL DISORDERS, SEXUAL DYSFUNCTION, BALDNESS, DIABETES, CANCER AND DISORDER OF IMMUNE REGULATION | ALLERGAN SALES, INC. | 2001-10-30 | — | — | US | disclosed |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2001-08-23 | — | — | US | disclosed |
| EP-0825980-B1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN SALES INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6204287-B1 | TREATING VISION DEFECTS | ALLERGAN SALES, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6037364-A | ADMINISTERING OCULAR HYPOTENSIVE AGENT; TREATING CARDIOVASCULAR DISORDERS; ANTICOAGULANTS | ALLERGAN SALES, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-5834498-A | OCULAR HYPOTENSIVE AGENTS | ALLERGAN (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0825980-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | Allergan (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036599-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN (US) | 1996-11-21 | — | — | WO | disclosed |
| US-4143051-A | GREATER TISSUE SPECIFICITY OF ACTION | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4113723-A | TISSUE SPECIFICITY | PFIZER INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4102894-A | TISSUE SPECIFICITY | PFIZER INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4080368-A | PROSTAGLANDINS | PFIZER INC. (US) | 1978-03-21 | — | — | US | disclosed |
| US-3980642-A | 15-Substitute D-ω-pentanorprostaglandins | PFIZER INC. (US) | 1976-09-14 | — | — | US | disclosed |
| US-3956284-A | INCREASED TISSUE SPECIFITY OF ACTION | PFIZER INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | POLB 1918/4885TDP1 4328/4885BRD4 4492/4885 |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGER2, PTGFR | POLB 1745/4885TDP1 4200/4885BRD4 4518/4885 |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | POLB 1897/4885TDP1 4342/4885BRD4 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.